Kevin Ferro is chief executive officer and chief investment officer of Vatera Holdings, the investment advisor to Vatera Healthcare Partners, and a co-founder of Vatera Healthcare Partners. In addition to being on the board of directors of Melinta Therapeutics, Mr. Ferro is the chairman of the boards of directors for ImmusanT, Inc., Arisaph Pharmaceuticals, Inc., and a member of the board of directors of Ekteino Laboratories, Inc. Mr. Ferro was chairman of the board of directors for Pearl Therapeutics until its sale to AstraZeneca in July 2013, and a member of the board of directors of Kos Pharmaceuticals, Inc. until its sale to Abbott Laboratories in 2006.
Previously, Mr. Ferro was global head of alternative investment strategies for Commerzbank AG, Germany’s second-largest listed bank, where he managed alternative investment programs for the bank and its clients. Prior to Commerzbank, Mr. Ferro was vice president at D. E. Shaw & Co. LP (1994-1998).
Mr. Ferro earned his B.A. from Harvard University.